Cambridge, Mass. — June 3, 2026 — Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company , appoints Jue Wang, PhD as Global Head of Business Development. The appointment is expected to further accelerate the commercialization of Insilico’s proprietary Pharma.AI platform and generative AI foundation ecosystem centered around MMAI Gym, as well as global out-licensing and R&D collaboration of Insilico's diverse portfolio of AI-driven therapeutic assets.
Dr. Wang joined Insilico in September 2021 as Director of Business Development and was promoted to Vice President of Business Development in February 2025. Throughout her tenure, she has played a pivotal role in expanding Insilico's global commercial footprint and translating its AI-driven discoveries into high-impact industry collaborations.
In the 2.75 billion-dollar deal with Eli Lilly announced in March 2026, Jue made significant contributions by leading the professional communication and cross-functional alignment, delivering another proof of AI possibilities and AI-driven quality. As the record-breaking collaboration drives significant attention and momentum, Insilico looks forward to wider communication with potential partners across the globe.
Besides, in the year of 2026 alone, Dr. Wang led multiple landmark out-licensing and global R&D collaborations both in drug discovery and AI model development with Human Longevity, Tenacia Biotechnology, ASKA Pharmaceutical, Liquid AI, CMS, Qilu Pharmaceutical, Hygtia Therapeutics, and Servier, totaling about USD 4 billion in potential deal value. More importantly, out-licensing collaborations with global partners including Menarini, TaiGen and Hisun are delivering steady results, with multiple clinical or R&D milestones reached and payments triggered.
"Over the past four and a half years at Insilico, I have witnessed a profound paradigm shift in the industry, where people turn their focus from questioning AI capabilities to practical execution and clinical validation," says Jue Wang, PhD, Global Head of Business Development at Insilico Medicine. "2026 is a vital year for Insilico, with significant success in business development, as well as major progress and important data readouts anticipated for our in-house pipelines."
Before joining Insilico, Dr. Wang accumulated over a decade of profound expertise in small-molecule novel drug discovery across roles at Shanghai Hengrui Pharmaceutical and GlaxoSmithKline (GSK), with a focus in the fields of tumor and CNS (central nervous system) diseases.
“Every AI-driven drug discovery (AIDD) company must be validated by robust pipelines, innovative products, and commercial profit, so business development is the absolute key,” says Alex Zhavoronkov, PhD, founder, CEO and CBO of Insilico Medicine. “Jue has demonstrated exceptional leadership and a profound understanding of both the science and the market since she joined us. Recounting the past successes she has delivered, we have immense hope and confidence that in her new position as Global Head of Business Development, she will continue to drive high-value alliances and empower Insilico’s commercial growth.”
Dr. Wang graduated with a PhD from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. She later completed her post-doctoral research practice in pharmacology at the University of California, Los Angeles (UCLA) and obtained her MBA from the University of Hong Kong.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com